title: Minimal-change disease secondary to etanercept.
abstract: Etanercept is a soluble tumor necrosis factor alpha (TNFα) receptor which is widely used in the treatment of rheumatoid arthritis, psoriasis and other autoimmune inflammatory disorders. It is known for its relative lack of nephrotoxicity; however, there are reports on the development of nephrotic syndrome associated with the treatment with TNFα antagonists. Here, we describe a patient with psoriasis who developed biopsy-proven minimal-change disease (MCD) shortly after initiating etanercept. Our case is unique in that the MCD resolved after discontinuation of this medication, notably without the use of corticosteroids, strongly suggesting a drug-related phenomenon.
authors.affiliation: Department of Internal Medicine , University of Washington , Seattle, WA , USA.
authors.forename: Mariko
authors.initials: M
authors.lastname: Koya
authors.affiliation: Department of Nephrology , University of Washington , Seattle, WA , USA.
authors.forename: Raimund
authors.initials: R
authors.lastname: Pichler
authors.affiliation: Department of Nephrology , University of Washington , Seattle, WA , USA.
authors.forename: J Ashley
authors.initials: JA
authors.lastname: Jefferson
keywords: etanercept; minimal-change disease; nephrotic syndrome; podocyte